Bcl-2 Family Proteins as Therapeutic Targets
- Author(s)
- Czabotar, PE; Lessene, G;
- Details
- Publication Year 2010-01-01,Volume 16,Issue #28,Page 3132-3148
- Journal Title
- CURRENT PHARMACEUTICAL DESIGN
- Publication Type
- Journal Article
- Abstract
- The mitochondrion provides the stage for the interplay of molecular interactions that regulate apoptosis via the intrinsic pathway. The release of apoptogenic factors from this compartment constitutes a critical juncture in this apoptotic pathway. Regulation of the integrity of the outer mitochondrial membrane (OMM) is the task of the Bcl-2 family of proteins. A network of interactions between the various subgroups of the family decides the apoptotic fate of a cell and, as such, an imbalance within this network can lead to a variety of disease states. In particular, over-expression of pro-survival Bcl-2 family proteins is a hallmark of many cancers. Here we discuss recent advances in targeting the Bcl-2 family with both peptides and small molecules.
- Publisher
- BENTHAM SCIENCE PUBL LTD
- Keywords
- CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE INHIBITOR; BH3 MIMETIC ABT-737; CELL LUNG-CANCER; DOMAIN PEPTIDE INTERACTION; STRUCTURE-BASED DESIGN; COLON-CARCINOMA CELLS; HUMAN-MELANOMA CELLS; PLATELET LIFE-SPAN; BH3-ONLY PROTEINS
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2010-01-01 12:00:00